Friday, September 30, 2016 11:32:16 AM
Or more precisely stated, it's naive to believe a silver bullet is a likely outcome.
Yes, I do believe that management believed they had a decent shot. The expert with whom I consulted in 2013 also believed that the most reasonable approach to curing viral infections was nanomedicine. The mechanism of action was also described to me as reasonable, in principle. The challenge, however, would be designing a ligand that would mimic the attachment proteins on the surface of a living cell. Clearly, this expert was wrong on the issue of scale-up of the nano-micelle production, as he felt that would not be a major technical hurdle. Yet this has become a major hurdle. If he was wrong about this, it's not surprising that Anil and Gene were as well.
The issue of the ligand design has not been brought up. However, it is my contention that even if the scale-up issue is solved the ligand issue will prove even more nettlesome.
The company has FAILED completely to be transparent with investors. I consider this to be an ethical issue at this time. But what most on this list seem not to appreciate is the psychological cycles tech-entrepreneurs go through when a dream-project goes off the rails. It's very hard to take in negative evidence when it begins to happen. And it does not happen all at once. It's a slow process and the mind keeps you from accepting it. So a psychological failing becomes an ethical failing.
Trendliner
Recent NNVC News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
- Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs • InvestorsHub NewsWire • 07/06/2023 03:16:37 PM
- NanoViricides, Inc. to Present at The Inaugural Ef Hutton Global Conference on May 10, 2023 in New York City • GlobeNewswire Inc. • 05/04/2023 10:45:00 AM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • BLO • Apr 25, 2024 8:52 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM